Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn't yet been approved ...
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...
Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
The generic liraglutide includes a Boxed Warning to advise ... "Today's approval underscores the FDA's continued commitment to advancing patient access to safe, effective, and high-quality generic ...
According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.
Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic. The FDA supports the development of generic drugs, such as GLP-1s ...